Tolvaptan is a vasopressin-2-receptor (V2R) antagonist approved to slow kidney function decline in adult patients with rapidly progressive ADPKD by reducing cAMP levels (Chebib and Torres 2021, Figure 1). The gene discussed is AVPR2; the disease is autosomal dominant polycystic kidney disease.